Feature Channels: Alzheimer's and Dementia

• share
• favorite_border

Having depression is known to increase your risk for developing Alzheimer’s disease. Now a new, preliminary study released today, February 24, 2021, reports that if people do develop Alzheimer’s disease, those with depression may start experiencing dementia symptoms about two years earlier than those who do not have depression. People with anxiety who develop Alzheimer’s may start experiencing dementia symptoms about three years earlier than those who do not have anxiety, according to the study that will be presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17 to 22, 2021.

• share
• favorite_border

Postmenopausal women who ate high levels of plant protein had lower risks of premature death, cardiovascular disease and dementia-related death compared with women who ate less plant proteins, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

• share
• favorite_border

The forthcoming 2021 Alzheimer’s Association Facts & Figures Report, as well as a new supplemental report “Race, Ethnicity and Alzheimer’s in America,” will be released March 2. Facts and Figures provides in-depth information on Alzheimer’s and other dementias in the U.S., including the latest stats on prevalence, mortality, costs, caregiving and other insights both nationally and with state by state data.

• share
• favorite_border

There is now keen interest in deeper investigation of infectious agents as the trigger of Alzheimer's disease

• share
• favorite_border

Researchers at Notre Dame found that elevated concentrations of proteins within the droplets triggered a folding event, increasing the potential for protein aggregation — or misfolding — which has been linked to neurological diseases including Alzheimer’s disease and ALS.

• share
• favorite_border

UC San Diego researchers have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer’s disease or Mild Cognitive Impairment, a condition that often precedes full-blown dementia.

• share
• favorite_border

No matter where you are in the world, the 2021 AAN Annual Meeting is one click away. Journalists can now register to attend the 73rd Annual Meeting of the American Academy of Neurology (AAN) being held virtually April 17-22, 2021. The AAN Annual Meeting is the world’s largest gathering of neurologists who come together to share the latest advances in neurologic research.

• share
• favorite_border

Areas of brain damage called white matter hyperintensities are commonly linked to vascular health problems. They have also been linked to Alzheimer’s disease. Now a new study has shown that white matter hyperintensities are also found in frontotemporal dementia. The study is published in the February 17, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. Frontotemporal dementia, which often affects people under the age of 65, mainly results in changes in personality, behavior and problems with language rather than memory.

• share
• favorite_border

Amyloid deposits in the brain increase the risk of dementia and strokes. Researchers at Washington University School of Medicine in St. Louis have identified an antibody that clears amyloid deposits from the brain without raising the risk of brain bleeds.

• share
• favorite_border

Alzheimer's advocacy groups taint their credibility by not revealing conflicts when they lobby FDA for drug approval

• share
• favorite_border

Five genes may play a key part in influencing if a person will contract Lewy body dementia, and possibly dementia from Parkinson's and Alzheimer’s diseases, according to a study published in Nature Genetics Feb. 15. The genes, BIN1, TMEM175, SNCA, APOE, and GBA, were identified by a team of scientists at the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, National Institutes of Health, and sequenced by The American Genome Center (TAGC), a series of state-of-the-art laboratories at the Uniformed Services University of the Health Sciences.

• share
• favorite_border

Sleep and health are inextricably connected.

• share
• favorite_border

DALLAS – Feb. 11, 2021 – A study led by UT Southwestern has identified a mechanism that controls the activity of proteins known as chaperones, which guide proteins to fold into the right shapes. The findings, published online today in Nature Communications, could shed light on hundreds of degenerative and neurodegenerative diseases caused by protein misfolding, such as Alzheimer’s, Parkinson’s, and Huntington’s, potentially leading to new treatments for these devastating conditions.

• share
• favorite_border

A study led by Case Western Reserve University researchers found that patients with dementia were at a significantly increased risk for COVID-19—and the risk was higher still for African Americans with dementia.

• share
• favorite_border

You might remember you ate cereal for breakfast but forget the color of the bowl. Or recall watching your partner put the milk away but can't remember on which shelf.

• share
• favorite_border

Although an expert FDA panel voted ten to one to withhold approval for a Biogen anti-Alzheimer's drug candidate, the Alzheimer's Association endorsed the compound. Serious questions have been raised about why, including conflict of interest.

• share
• favorite_border

NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders.

• share
• favorite_border

Amyloid-beta and tau are the two key abnormal protein deposits that accumulate in the brain during the development of Alzheimer's disease, and detecting their buildup at an early stage may allow clinicians to intervene before the condition has a chance to take hold.

• share
• favorite_border

• share
• favorite_border

As yet there is no prescription drug to cure mild cognitive impairment (MCI), often a harbinger of Alzheimer's disease. Medical research journals reveal curcumin can sometimes bolster cognition. It merits a try.